Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases in the United States. The company is headquartered in Waltham, Massachusetts.
| Revenue (TTM) | $55.87M |
| Gross Profit (TTM) | $51.92M |
| EBITDA | $-81.16M |
| Operating Margin | -313.90% |
| Return on Equity | -60.30% |
| Return on Assets | -29.60% |
| Revenue/Share (TTM) | $0.25 |
| Book Value | $0.72 |
| Price-to-Book | 1.60 |
| Price-to-Sales (TTM) | 5.80 |
| EV/Revenue | 2.659 |
| EV/EBITDA | 0.78 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 21.60% |
| Shares Outstanding | $294.61M |
| Float | $214.30M |
| % Insiders | 7.09% |
| % Institutions | 83.80% |
Volatility is currently expanding